Active drug shortages in the U.S. rose for the second consecutive quarter in 2026, reaching 223 in the first quarter, according to a recent report from the American Society of Health-System Pharmacists. Meanwhile, the FDA’s own database — which uses a narrower classification — lists 76 drugs currently in shortage, as of May 6.
The database is updated daily to reflect manufacturing recoveries, regulatory actions and how shortages are classified — not solely day-to-day availability at the hospital level.
Here are seven recent drug shortages, according to the FDA database:
- Cisatracurium besylate injection: Hospira, a Pfizer company, is discontinuing the 2- and 10-milligram/milliliter formulations, with supply expected to run out by late June. Posted May 6.
- Bupivacaine hydrochloride injection: Kindos Pharmaceuticals discontinued 2.5-, 5- and 7.5-milligram/milliliter presentations May 5.
- Lamotrigine extended-release tablets: Par Health discontinued all six strengths — 25 milligrams through 300 milligrams April 29.
- Crinecerfont capsules: Neurocrine Biosciences is discontinuing only the 25-milligram Crenessity capsule; the 50-, 100-milligram capsules and oral solution will remain on the market as of April 28.
- Etravirine tablets: Janssen discontinued the 100-milligram Intelence tablets April 28.
- Furosemide injection: Gland Pharma, distributed by Sagent Pharmaceuticals, discontinued the 10-milligram/milliliter formulation April 28.
- Palbociclib capsules: Pfizer is discontinuing the 75- and 100-milligram Ibrance capsules; the tablet formulation in both strengths will continue to be manufactured, as of April 22.
